Photo by Spencer Platt/Getty Images

The IPO window is no longer just open. It's been shattered, had its frame removed and is now a chasmal cavity for capital.

Bottom line: This should be the year's busiest week for new U.S. listings, with the boom being driven by factors like political uncertainty and increased M&A activity.

  • U.S. IPO pricings are up 35% over last year, per Renaissance Capital, while proceeds raised and filings are up 33% and 31%, respectively.
  • A dozen companies are set to price this week. And it's a diverse group, including pre-revenue biotechs, an LBO-backed retailer (BJ's Wholesale) and a hairy under-corn (Domo).
  • Ten priced last week (not including three SPACs), many after increasing their number of offered shares.
  • Six companies filed for IPOs last Friday, and Hong Kong this morning got official paper work for Meituan-Dianping, which could be valued at $60 billion.
  • Five of those new offerings were from biopharma companies. Nasdaq says that 30 biopharma issuers have raised $2.5 billion already this year (86% of all healthcare IPO proceeds), competed to 43 raising $4 billion all last year and 32 raising $1.9 billion in 2016.
  • 83% of this year's biopharma IPOs have priced at or above its proposed IPO range, with Nasdaq healthcare listings boss Jordan Saxe saying "crossover investors" are seeking exposure to several different new types of biopharma technology.

IPO insiders are unsure as to why this is happening now as opposed to, say, 12 months ago. After all, it's not like there's been a pullback of private capital alternatives for later-stage companies. But they do offer three drivers:

  1. Strong pricing and aftermarket activity so far in 2018. Renaissance's U.S. IPO index was basically even with the S&P 500 last June, but has easily outpaced it since this past March.
  2. Increased M&A activity, which prompts companies to at least file for IPOs. Or, put another way, chumming the water.
  3. Growing uncertainty about what the 2018 midterms may mean for markets, which is being exacerbated by concerns over trade wars and new restrictions on Chinese investments. There is usually a mini-boom this time of year (getting ahead of August vacations), but this one is more pronounced.

Go deeper

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Politics: Ex-FDA chief: Pence campaigning after COVID exposure puts others at risk — Mark Meadows: "We are not going to control the pandemic"— COVID-19 looms over White House Halloween celebrations.
  2. Health: 13 states set single-day coronavirus case records last week — Fauci says maybe we should mandate masks if people don't wear themU.S. reports over 80,000 new cases for second consecutive day.
  3. World: Italy tightens restrictions Spain declares new state of emergency.

Amy Coney Barrett's immediate impact

Illustration: Eniola Odetunde/Axios

In her first week on the job, Amy Coney Barrett may be deciding which votes to count in the presidential election. By her third week, she’ll be deciding the fate of the Affordable Care Act.

Where it stands: The Senate votes on Barrett’s nomination tomorrow. If she’s confirmed, Chief Justice John Roberts is expected to swear her in at the Supreme Court within hours, an administration official tells Axios.

Texas Democrats beg Biden to spend now

Photo: Ron Jenkins/Getty Images

The Biden campaign is rebuffing persistent pleas from Texas Democrats to spend at least $10 million in the Lone Star state, several people familiar with the talks tell Axios.

Why it matters: If Texas — which has 38 electoral votes and is steadily getting more blue, but hasn't backed a Democrat for president since 1976 — flipped to the Biden column, it would be game over. But the RealClearPolitics polling average stubbornly hovers at +2.6 for Trump — and Team Biden appears more focused on closer targets.